Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 140 clinical trials
  • 0 views
  • 24 Oct, 2022
  • 91 locations
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of SAR442720 in Combination With Other Agents in Participants With Advanced Malignancies

combination with pembrolizumab. Part 3A To define the MTD and RP2D for the combination of SAR442720 and adagrasib in participants with KRAS G12C NSCLC To characterize the safety

BRAF
KRAS
measurable disease
cancer
  • 0 views
  • 21 Oct, 2022
  • 16 locations
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of SAR442720 in Combination With Other Agents in Participants With Advanced Malignancies

combination with pembrolizumab. Part 3A To define the MTD and RP2D for the combination of SAR442720 and adagrasib in participants with KRAS G12C NSCLC To characterize the safety

pembrolizumab
BRAF
KRAS
cancer
solid neoplasm
  • 68 views
  • 21 Oct, 2022
  • 15 locations
An Open-label, Multi-center, Phase I, Dose Finding Study of Oral TNO155 in Adult Patients With Advanced Solid Tumors

The purpose of this first in human (FIH) trial is to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in adult patients with advanced solid tumors in selected indications.

  • 297 views
  • 28 Oct, 2022
  • 11 locations
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (TITANIA) (TITANIA)

The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Participants should …

  • 6 views
  • 27 Oct, 2022
  • 92 locations
A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter Variable Length Study to Assess the Efficacy and Safety of PT010 Relative to PT009 and Symbicort® in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care

  • 130 views
  • 18 Oct, 2022
  • 235 locations
Tarlox and Sotorasib in Patients With KRAS G12C Mutations

This is a Phase IB dose expansion trial with safety lead-in evaluating the safety, clinical activity/efficacy of the combination of tarloxotinib and sotorasib in patients with KRAS G12C mutation

platelet count
lung carcinoma
KRAS
cancer chemotherapy
  • 0 views
  • 21 Apr, 2022
  • 1 location
The LIMIT KRAS Mutant NSCLC Trial: Lysosome Inhibition to Enhance MAPK Inhibition Targeting KRAS Mutant NSCLC: A Phase 2 Open Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

other cancers. The dose of HCQ will also be fixed based on ongoing phase I studies. Eligible subjects will have lung cancer that has a mutation in a key cancer gene called KRAS, and the cancer has

lung carcinoma
systemic therapy
KRAS
Accepts healthy volunteers
  • 0 views
  • 21 Oct, 2022
  • 1 location
Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC

This is a single arm study, conducted at two centers, of neoadjuvant sotorasib in treatment naïve patients with stage Ib-IIIa NSCLC. The study will accrue 25 patients in all. Patients must have been deemed surgically resectable and physiologically fit for surgery by a thoracic surgeon prior to enrollment.

neutrophil count
KRAS
measurable disease
  • 0 views
  • 04 Oct, 2022
  • 1 location
  • 0 views
  • 04 Oct, 2022
  • 4 locations